Pathophysiology of thrombotic thrombocytopenic purpura.

The discovery of a disintegrin-like and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS13) revolutionized our approach to thrombotic thrombocytopenic purpura (TTP). Inherited or acquired ADAMTS13 deficiency allows the unrestrained growth of microthrombi that are composed of von Willebrand factor and platelets, which account for the thrombocytopenia, hemolytic anemia, schistocytes, and tissue injury that characterize TTP. Most patients with acquired TTP respond to a combination of plasma exchange and rituximab, but some die or acquire irreversible neurological deficits before they can respond, and relapses can occur unpredictably. However, knowledge of the pathophysiology of TTP has inspired new ways to prevent early deaths by targeting autoantibody production, replenishing ADAMTS13, and blocking microvascular thrombosis despite persistent ADAMTS13 deficiency. In addition, monitoring ADAMTS13 has the potential to identify patients who are at risk of relapse in time for preventive therapy.

[1]  P. Knöbl,et al.  Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura. , 2017, Blood.

[2]  H. Deckmyn,et al.  N-acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura. , 2017, Blood.

[3]  X. Zheng,et al.  Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura. , 2016, Blood advances.

[4]  S. Vesely,et al.  Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura. , 2016, Blood.

[5]  A. E. Eşkazan,et al.  Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura , 2016, Annals of Hematology.

[6]  Alexandra Rousseau,et al.  Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study , 2016, American journal of hematology.

[7]  S. Vesely,et al.  Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. , 2016, Blood.

[8]  Tina Dutt,et al.  Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura , 2016, British journal of haematology.

[9]  L. Villarreal-Martínez,et al.  More about low-dose rituximab and plasma exchange as front-line therapy for patients with thrombotic thrombocytopenic purpura , 2016, Hematology.

[10]  B. Jilma,et al.  Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. , 2016, The New England journal of medicine.

[11]  Junmei Chen,et al.  High-density lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion. , 2016, Blood.

[12]  L. Ye,et al.  Long-term remission induced by low-dose rituximab for relapsed and refractory thrombotic thrombocytopenic purpura: A report of two cases. , 2015, Experimental and therapeutic medicine.

[13]  G. Remuzzi,et al.  ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[14]  C. Tersteeg,et al.  Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[15]  D. Chauveau,et al.  Risk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic Purpura , 2015, Medicine.

[16]  S. Diamond,et al.  Pathological von Willebrand factor fibers resist tissue plasminogen activator and ADAMTS13 while promoting the contact pathway and shear‐induced platelet activation , 2015, Journal of thrombosis and haemostasis : JTH.

[17]  Ying Zheng,et al.  Flow-driven assembly of VWF fibres and webs in in vitro microvessels , 2015, Nature Communications.

[18]  M. Poncz,et al.  Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models. , 2015, Blood.

[19]  Junmei Chen,et al.  Hypochlorous Acid Generated by Neutrophils Inactivates ADAMTS13 , 2014, The Journal of Biological Chemistry.

[20]  H. Watson,et al.  Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. , 2014, Blood.

[21]  L. Galicier,et al.  Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. , 2014, Blood.

[22]  A. K. Davis,et al.  Neurological symptoms as the sole presentation of relapsed thrombotic thrombocytopenic purpura without microangiopathic haemolytic anaemia , 2014, Thrombosis and Haemostasis.

[23]  C. Denis,et al.  GpIbα-VWF blockade restores vessel patency by dissolving platelet aggregates formed under very high shear rate in mice. , 2014, Blood.

[24]  C. Casari,et al.  Expression of a structurally constrained von Willebrand factor variant triggers acute thrombotic thrombocytopenic purpura in mice. , 2014, Blood.

[25]  C. Maas,et al.  Plasmin Cleavage of von Willebrand Factor as an Emergency Bypass for ADAMTS13 Deficiency in Thrombotic Microangiopathy , 2014, Circulation.

[26]  J. George,et al.  Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry , 2013, Hämostaseologie.

[27]  B. Nourbakhsh,et al.  Pearls and oy-sters: acute ischemic stroke caused by atypical thrombotic thrombocytopenic purpura. , 2013, Neurology.

[28]  J. Mira,et al.  High prevalence of infectious events in thrombotic thrombocytopenic purpura and genetic relationship with toll‐like receptor 9 polymorphisms: experience of the French Thrombotic Microangiopathies Reference Center , 2013, Transfusion.

[29]  M. Scully,et al.  Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse , 2013, Journal of thrombosis and haemostasis : JTH.

[30]  Preethi B Reddy,et al.  Atypical thrombotic thrombocytopenic purpura in a middle‐aged woman who presented with a recurrent stroke , 2013, American journal of hematology.

[31]  S. Opat,et al.  ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. , 2013, The New England journal of medicine.

[32]  A. ten Brinke,et al.  Preferential HLA-DRB1*11-dependent presentation of CUB2-derived peptides by ADAMTS13-pulsed dendritic cells. , 2012, Blood.

[33]  H. Deckmyn,et al.  Inhibition of von Willebrand factor-platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons. , 2012, Blood.

[34]  D. Consonni,et al.  ADAMTS‐13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura , 2012, Journal of thrombosis and haemostasis : JTH.

[35]  R. Gibbs,et al.  Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. , 2012, Blood.

[36]  H. Schwarz,et al.  A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13. , 2012, Blood.

[37]  É. Azoulay,et al.  Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. , 2012, Blood.

[38]  H. Kwaan,et al.  Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. , 2012, Blood.

[39]  B. Lämmle,et al.  Initial experience from a double‐blind, placebo‐controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura , 2012, American journal of hematology.

[40]  K. Kolev,et al.  Modulation of the von Willebrand factor-dependent platelet adhesion through alternative proteolytic pathways , 2012, Thrombosis research.

[41]  J. Baddley,et al.  Incidence and risk factors for Progressive Multifocal Leukoencephalopathy among patients with selected rheumatic diseases , 2012, Arthritis care & research.

[42]  G. Choukroun,et al.  Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center , 2012, Critical care medicine.

[43]  K. Tyler,et al.  Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. , 2011, Archives of neurology.

[44]  P. D. de Groot,et al.  Cleavage of von Willebrand Factor by Granzyme M Destroys Its Factor VIII Binding Capacity , 2011, PloS one.

[45]  J. Cavenagh,et al.  A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. , 2011, Blood.

[46]  S. Lancellotti,et al.  Oxidized von Willebrand factor is efficiently cleaved by serine proteases from primary granules of leukocytes: divergence from ADAMTS‐13 , 2011, Journal of thrombosis and haemostasis : JTH.

[47]  P. Stanssens,et al.  Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. , 2011, Blood.

[48]  T. Miyata,et al.  Natural history of Upshaw–Schulman syndrome based on ADAMTS13 gene analysis in Japan , 2011, Journal of thrombosis and haemostasis : JTH.

[49]  H. Ehrlich,et al.  Recombinant ADAMTS13 normalizes von Willebrand factor‐cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies , 2011, Journal of Thrombosis and Haemostasis.

[50]  J. Moake,et al.  N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. , 2011, The Journal of clinical investigation.

[51]  Junmei Chen,et al.  Shear stress-induced unfolding of VWF accelerates oxidation of key methionine residues in the A1A2A3 region. , 2010, Blood.

[52]  H. Deckmyn,et al.  Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus). , 2010, Blood.

[53]  H. Deckmyn,et al.  Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura , 2010, Journal of thrombosis and haemostasis : JTH.

[54]  X. Zheng,et al.  Factor VIII and Platelets Synergistically Accelerate Cleavage of von Willebrand Factor by ADAMTS13 under Fluid Shear Stress* , 2010, The Journal of Biological Chemistry.

[55]  H. Ehrlich,et al.  Preclinical Testing of Human Recombinant von Willebrand Factor: ADAMTS13 Cleavage Capacity in Animals as Criterion for Species Suitability , 2010, Seminars in thrombosis and hemostasis.

[56]  S. Vesely,et al.  Survival and relapse in patients with thrombotic thrombocytopenic purpura. , 2010, Blood.

[57]  Junmei Chen,et al.  Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. , 2010, Blood.

[58]  R. Montgomery,et al.  Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. , 2009, Blood.

[59]  Cheng-Zhong Zhang,et al.  Mechanoenzymatic Cleavage of the Ultralarge Vascular Protein von Willebrand Factor , 2009, Science.

[60]  J. Dieleman,et al.  Unilateral intracarotid injection of holmium microspheres to induce bilateral MRI-validated cerebral embolization in rats , 2009, Journal of Neuroscience Methods.

[61]  J. Schmitto,et al.  Histological changes in a model of chronic heart failure induced by multiple sequential coronary microembolization in sheep. , 2008, The Journal of cardiovascular surgery.

[62]  Shili Lin,et al.  Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse , 2008, British journal of haematology.

[63]  A. Chauhan,et al.  The combined roles of ADAMTS13 and VWF in murine models of TTP, endotoxemia, and thrombosis. , 2008, Blood.

[64]  F. Fabris,et al.  ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission , 2008, Haematologica.

[65]  K. Shim,et al.  Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress. , 2008, Blood.

[66]  B. Sullenger,et al.  Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers. , 2007, Oligonucleotides.

[67]  G. Shaw,et al.  The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time , 2007, Thrombosis and Haemostasis.

[68]  A Alexander-Katz,et al.  Shear-induced unfolding triggers adhesion of von Willebrand factor fibers , 2007, Proceedings of the National Academy of Sciences.

[69]  É. Oksenhendler,et al.  Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. , 2007, Blood.

[70]  D. Meyer,et al.  Desmopressin, an unexpected link between nocturnal enuresis and inherited thrombotic thrombocytopenic purpura (Upshaw‐Schulman syndrome) , 2006, Journal of thrombosis and haemostasis : JTH.

[71]  A. Chauhan,et al.  Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. , 2005, The Journal of clinical investigation.

[72]  Yoshihiro Kokubo,et al.  FRETS‐VWF73, a first fluorogenic substrate for ADAMTS13 assay , 2005, British journal of haematology.

[73]  P. Lenting,et al.  The von Willebrand factor self‐association is modulated by a multiple domain interaction , 2005, Journal of thrombosis and haemostasis : JTH.

[74]  G. V. van Montfrans,et al.  Microangiopathic Hemolysis and Renal Failure in Malignant Hypertension , 2005, Hypertension.

[75]  M. Overman,et al.  Worsening of thrombotic thromboctyopenic purpura symptoms associated with desmopressin administration , 2004, Thrombosis and Haemostasis.

[76]  K. Lassoued,et al.  Severe ADAMTS13 Deficiency in Adult Idiopathic Thrombotic Microangiopathies Defines a Subset of Patients Characterized by Various Autoimmune Manifestations, Lower Platelet Count, and Mild Renal Involvement , 2004, Medicine.

[77]  L. Goodnough,et al.  Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. , 2004, Blood.

[78]  G. Hutchins,et al.  Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. , 2003, Archives of pathology & laboratory medicine.

[79]  S. Tamura,et al.  Contribution of von Willebrand Factor to Thrombus Formation on Neointima of Rabbit Stenotic Iliac Artery Under High Blood-Flow Velocity , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[80]  Kazuo Fujikawa,et al.  ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. , 2002, Blood.

[81]  Bahman Anvari,et al.  Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. , 2002, Blood.

[82]  H. Tsai.  Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura , 2002, Journal of Molecular Medicine.

[83]  H. Deckmyn,et al.  Inhibition of Platelet Glycoprotein Ib, Glycoprotein IIb/IIIa, or Both by Monoclonal Antibodies Prevents Arterial Thrombosis in Baboons , 2002, Arteriosclerosis, Thrombosis and Vascular Biology.

[84]  J. Sixma,et al.  Functional self-association of von Willebrand factor during platelet adhesion under flow , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[85]  B. Lämmle,et al.  Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. , 2001, Best practice & research. Clinical haematology.

[86]  Craig S. Wong,et al.  Von Willebrand Factor and Von Willebrand Factor-Cleaving Metalloprotease Activity in Escherichia coli O157:H7-Associated Hemolytic Uremic Syndrome , 2001, Pediatric Research.

[87]  A. Girolami,et al.  Post-DDAVP Thrombocytopenia in Type 2B von Willebrand Disease Is not Associated with Platelet Consumption: Failure to Demonstrate Glycocalicin Increase or Platelet Activation , 1999, Thrombosis and Haemostasis.

[88]  D. Deykin,et al.  Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. , 1982, The New England journal of medicine.

[89]  G. Hutchins,et al.  The heart and cardiac conduction system in thrombotic thrombocytopenic purpura. A clinicopathologic study of 17 autopsied patients. , 1979, Annals of internal medicine.

[90]  J. Ultmann,et al.  THROMBOTIC THROMBOCYTOPENIC PURPURA: REPORT OF 16 CASES AND REVIEW OF THE LITERATURE , 1966 .

[91]  U. Budde,et al.  Plasmin Cleaves Von Willebrand Factor at K1491-R1492 in the A1–A2 Linker Region in a Shear- and Glycan-Dependent Manner In Vitro , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[92]  R. Aisina,et al.  The covalent or non-covalent modification of streptokinase with polyethylene glycol improves its properties , 2016 .

[93]  A. Rajasekhar,et al.  A case series of atypical presentations of thrombotic thrombocytopenic purpura , 2012, Journal of clinical apheresis.

[94]  F. Nicoli,et al.  Stroke in a young patient treated by alteplase heralding an acquired thrombotic thrombocytopenic purpura , 2011, Journal of clinical apheresis.

[95]  B. Lämmle,et al.  von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. , 2004, Seminars in hematology.

[96]  J. Sixma,et al.  Adhesion of blood platelets is inhibited by VCL, a recombinant fragment (leucine504 to lysine728) of von Willebrand factor. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[97]  J. Kelton,et al.  Comparison of Plasma Exchange With Plasma Infusion in the Treatment of Thrombotic Thrombocytopenia Purpura , 1992 .

[98]  T. Hara,et al.  Factor VIII concentrate-responsive thrombocytopenia, hemolytic anemia, and nephropathy. Evidence that factor VIII:von Willebrand factor is involved in its pathogenesis. , 1986, The American journal of pediatric hematology/oncology.